FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically recombinant cell CYTO-CAR-YT-Lact, exhibiting high cytotoxic activity with respect to PSMA-positive human cancer cells. Line is produced in two stages: first, a YT cell line is transduced by lentiviral particles coding a chimeric antigenic receptor against PSMA protein and a recombinant lactaptin peptide, and then performing produced CAR-YT-Lact line transduction by lentiviral particles pre-processed using recombinant lentiviral plasmids lentiCRISPRv2-Shp2g1 and lentiCRISPRv2-Shp2g2, characterized in accordance with physical maps presented in fig. 1 and fig. 3, following features: have size of 13012 base pairs, encoding main functional-structural elements of the CRISPR/Cas9 system and consisting of the following elements: a human snRNA U6 promoter; sgRNA to third and fifth exons of PTPN11 gene, respectively; human promoter EF1a; chimeric protein composition Cas9-NLS-FLAG-P2A-PURO.
EFFECT: invention increases cytotoxic activity in relation to PSMA-positive human cancer cells.
1 cl, 8 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT HUMAN BREAST CANCER CELL LINE BRCCH4E-134, EXPRESSING HUMAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN | 2019 |
|
RU2726541C1 |
| PSCA-CAR-YT CELL LINE HAVING SURFACE EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS AND EXHIBITING CYTOTOXIC ACTIVITY ON PSCA-POSITIVE HUMAN CANCER CELLS | 2018 |
|
RU2712901C1 |
| NK CELL LINE EXPRESSING PSMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND SECRETING CD47/SIRPA INTERACTION BLOCKER | 2020 |
|
RU2757353C1 |
| RECOMBINANT EL1 PEPTIDE HAVING CYTOTOXIC ACTIVITY RELATIVE TO HUMAN CANCER CELLS | 2017 |
|
RU2683221C1 |
| RECOMBINANT OF VV-GMCSF / LACT-DGF VIRUS OF OSVOVICINE, OF ONLY-COLIC ACTIVITY AND PRODUCING SECRETABLE CHIMERIC WHITE, CONTAINING FROM GRANULOCYTE-MACROPHAGAL COLONISTIMULATING HUMAN FACTOR AND ONCOTOXIC PROTEIN OF LACTAPTIN | 2016 |
|
RU2630672C1 |
| METHOD FOR PRODUCING CYTOTOXIC T-LYMPHOCYTES EXPRESSING CHIMERIC RECEPTORS | 2018 |
|
RU2714380C1 |
| RECOMBINANT STRAIN OF VV-GMCSF-S-Lact VACCINIA VIRUS, WITH ONCOLYTIC ACTIVITY, PRODUCING GRANULOCYTOR-MACROPHAGAL COLONY-STIMULATING HUMAN FACTOR AND SECRETED FORM OF LACTAPTIN ONCOTOXIC PROTEIN | 2016 |
|
RU2621861C1 |
| RECOMBINANT PLASMID pET-15b_T3_RL DNA PROVIDING SYNTHESIS OF RECOMBINANT FUSION PROTEIN CONSISTING OF TUMOR-SPECIFIC PEPTIDES AND ANTITUMOR PEPTIDE RL2, AND RECOMBINANT FUSION PROTEIN POSSESSING ANTI-TUMOR ACTIVITY AGAINST HUMAN BREAST CANCER | 2016 |
|
RU2619053C1 |
| RECOMBINANT PLASMID pET-15b_T1_RL DNA PROVIDING SYNTHESIS OF RECOMBINANT FUSION PROTEIN CONSISTING OF TUMOR-SPECIFIC PEPTIDES AND ANTITUMOR PEPTIDE RL2, AND RECOMBINANT FUSION PROTEIN POSSESSING CYTOTOXIC ACTIVITY AGAINST CANCER CELLS AND TARGETED PROPERTIES AGAINST TUMOR TISSUE | 2016 |
|
RU2619050C1 |
| RECOMBINANT CELL LINE TMDK562-15 SHOWING THE ABILITY TO ACTIVATE AND PROLIFERATE HUMAN NK CELLS | 2022 |
|
RU2803178C1 |
